Veru has completed full enrollment in its Phase 2b PLATEAU clinical trial, exceeding the 200-patient target for a combination regimen of enobosarm and semaglutide aimed at preserving lean muscle mass during GLP-1-driven weight loss.
The trial's central hypothesis addresses one of the most persistent clinical concerns in the GLP-1 weight-management category: that rapid body weight reduction induced by semaglutide and similar agents carries a significant risk of skeletal muscle loss alongside fat reduction. Enobosarm is a selective androgen receptor modulator (SARM) designed to preferentially stimulate muscle anabolism without the broader androgenic effects associated with traditional hormone therapies. By pairing it with semaglutide, Veru is targeting what the company frames as "high quality weight loss" — a metric increasingly important to clinicians and, by extension, to the functional nutrition and supplement sectors tracking GLP-1-adjacent product development.
Why the Muscle Question Matters
The GLP-1 receptor agonist market has reshaped weight-management conversations across pharmaceutical, nutraceutical, and functional food channels alike. Estimates from industry analysts place the addressable market for GLP-1-supportive products — including protein supplements, leucine-enriched formulations, creatine, and resistance-training-adjacent nutrition — in the multi-billion-dollar range over the next five years, as millions of patients on semaglutide or tirzepatide seek ancillary support for body composition. For operators in the protein and sports nutrition segment, the clinical validation of muscle-preservation endpoints during GLP-1 therapy represents a meaningful commercial signal.
Enobosarm's mechanism — selective androgen receptor modulation — has been studied in oncology-related muscle-wasting contexts, giving it a clinical pedigree that distinguishes it from over-the-counter muscle-support ingredients. If PLATEAU data demonstrate statistically significant lean mass retention at a defined clinical endpoint, the findings could inform finished-formulation positioning and structure-function claim strategies across the broader weight management and GLP-1 category.
What Full Enrollment Signals
Exceeding a pre-specified 200-patient enrollment ceiling is operationally significant: it reduces the risk of underpowered results and strengthens the statistical framework for Phase 3 planning. Trial readouts from a fully enrolled Phase 2b cohort typically arrive within 12 to 18 months of last-patient-in, placing potential data disclosure in late 2026 or 2027 — a window that coincides with intensifying competition among GLP-1 augmentation strategies across both pharmaceutical and nutraceutical pipelines.
For ingredient suppliers, contract manufacturers, and brand developers monitoring the GLP-1 adjacency space, the PLATEAU milestone underscores the direction of clinical investment: combination protocols that treat weight quality — not just weight quantity — as the primary endpoint. That framing is already influencing how functional food and beverage brands position high-protein, muscle-supportive SKUs to the growing cohort of GLP-1 users in retail and direct-to-consumer channels.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.